Tag Archives: Alternative Cancer Therapy

Targeting Proteins May Prevent Metastasis of Cancers

Targeting Proteins May Prevent Metastasis of Cancers
Targeting Proteins May Prevent Metastasis of Cancers

New research has uncovered the existence of a protein that helps tumors spread, enabling their capacity to grow blood vessels. Could targeting this protein in cancer treatment experimentation lead to a new potential cure?

Not So Fast!
Published in the journal Oncogene, the study involved laboratory experiments blocking the protein latent TGF-beta binding protein 3 (LTBP3), prevented tumors from effectively metastasizing. A collaborative effort between multiple researchers, the investigation began based on the observation that lower levels of the protein LTBP3 correlated to an improved survival outcome in those with certain types of cancer.

A Complex Dynamic
The LTBP3 protein binds to a substance called TGF-beta to metastasize. TGF-beta presents a double-edged sword, either aiding the spread of tumors – or putting a halt to metastasis. Our bodies rely on TGF-beta to function properly. In early stages, it suppresses cancer growth. However in advanced cancers, it transforms and promotes tumor growth. The cancer treatment trick? To control the harmful effects of TGF-beta without disturbing normal cell function.

A Confirmed Association
As researchers looked closer into the interplay of LTBP3 and TGF-beta using head and neck carcinoma and fibroscarcoma in mice and chicks, the scientists discovered LTBP3 helps tumors grow blood vessels, and primary tumors could not metastasize properly in its absence. This corroborated the previous research associating lower levels of the LTBP3 protein with better patient outcomes. Further research into this complex dynamic is highly anticipated.

Looking for a more targeted cancer treatment plan? Issels® unique, highly-personalized cancer treatment protocols are clinically-proven, scientifically-backed, and compatible with both traditional and alternative treatment therapies. Learn more about the Issels® immunotherapy difference today.

New Medications Inhibit Cancer Cloaking by IDO Enzyme

New Medications Inhibit Cancer Cloaking by IDO Enzyme
New Medications Inhibit Cancer Cloaking by IDO Enzyme

 Cancer treatment research often focuses on destroying the defenses that prevent the immune system from attacking tumor cells. A promising new immunotherapy drug works by disabling one of these protective enzymes.

Disabling Cancer’s Protective Shield

IDO is an enzyme that shields a fetus from the mother’s immune system, which would perceive the fetus as an infection. During the early 2000s, researchers in Belgium discovered that tumors also express IDO, depriving T-cells of tryptophan, an amino acid that fuels T-cells.

Incyte, a small firm in Wilmington, Delaware, was the first to develop epacadostat, a drug that suppresses production of IDO. The company presented their findings, including results of the first meaningful trial in treating lung cancer, at last June’s meeting of the American Society of Clinical Oncology.

The Medical Community Reacts

According to Vamil Divan, an analyst at Credit Suisse, Incyte’s impressive presentation generated major interest in doctors and investors alike. Incyte also confirmed earlier research that successfully paired epacadostat with Keytruda, another immunotherapy drug, without a significant increase in side effects.

Approval of the combined epacadostat-Keytruda cancer treatment is pending results of a final trial, expected sometime next year. Merck and Bristol-Myers, two of Incyte’s initial collaborators, are working on development of their own IDO inhibitors.

Issels®: Pioneers of Immunotherapy for Cancer Treatment

IDO inhibitors are just the latest development in the field of immunotherapy, which boosts the power of your own immune system to fight cancer. Contact us to learn why Issels® has been in the forefront of using state-of-the-art immunotherapy to achieve long-term remission in patients of all ages with all forms of cancer.

FDA Quickly Approves New One-of-a-Kind Cancer Treatment

There is New Hope for Cancer Patients.
There is New Hope for Cancer Patients.

Researchers have made a number of significant breakthroughs in cancer treatment, but a recent development has the healthcare community particularly excited. The Food and Drug Administration (FDA) has approved a drug that treats tumors based on a genetic abnormality.

Keytruda: A Landmark in Immunotherapy for Cancer

Pembrolizumab, marketed under the trade name Keytruda, was tested on a trial group of 86 patients. The results were remarkable: 66 patients saw their tumors shrink and stabilize, while the tumors in 18 of them disappeared with no recurrence.

What’s different about Keytruda? It’s the first drug that attacks tumors from a shared genetic profile rather than the actual location of the tumor. A prospective patient first undergoes testing to determine whether he or she is a genetic match for the mutations targeted by Keytruda.

Current and Future Possibilities

At present, Keytruda is approved for treating only select forms of advanced bladder, lung and melanoma tumors. The drug will be effective for approximately four percent of cancer patients, which still equates to tens of thousands of people.

Scientists are encouraged by the possibility of further treatment methods tailored to a patient’s specific genetic profile. This ability would greatly enhance development of more accurate targeting and treatment.

Advanced Immunotherapy for Cancer Treatment from Issels®

Issels® uses genomic testing to determine a patient’s individual treatment needs. We then use the information to tailor a personalized immunotherapy for cancer program including methods such as vaccines and NK cells.

We have helped patients with all forms of cancer achieve long-term remission. Contact us to learn more about why the Issels® difference may be right for you.

Aspirin May Actually Cut Cancer Risk

Aspirin As A Cancer Reducer?
Aspirin As A Cancer Reducer?

Many doctors already recommend taking an aspirin a day to decrease the risk of stroke and heart attack, but recent cancer news indicates that swallowing an aspirin a day may also decrease certain types of cancer risk.

Cutting Cancer Risk

British researchers at the Wolfson Institute of Preventive Medicine in London have found strong evidence that people age 50 to 65 could cut their risk of contracting colon, esophageal and stomach cancers by taking one baby aspirin (75 to 81 milligrams) a day for 10 years.

“Taking aspirin daily looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity,” one British researcher told USA Today.

Beware of Side Effects

However, both study researchers and other cancer experts recommend talking to your doctor before beginning a preventative aspirin regimen. Aspirin can cause gastrointestinal bleeding and may cause other adverse and potentially dangerous side effects, particularly when taken with certain other drugs such as blood thinners.

Also of concern, a study reported by Newser.com found that long-term aspirin therapy “may be a factor in macular degeneration,” an age-related eye disease that can result in eventual blindness. Due to the increased risk of aspirin-related bleeding with age, British researchers generally recommended halting daily aspirin therapy after 10 years.

Benefits Outweigh Side Effects

“There was clear evidence that the benefits vastly outweigh the side effects,” study leader Dr. Jack Cuzick told the New York Times.

While cancer news shows support for use of long-term aspirin therapy to prevent cancer growing, questions remain. We recommend talking to your Issels cancer treatment team to see if aspirin therapy is right for you.

New Evidence Demonstrates Immunotherapy’s Effectiveness against Cancer

 

Alternative Healing
Alternative Healing

Immunotherapy was again validated as an effective means of fighting cancer and prolonging life when new cancer research results were presented Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago. As reported in the Wall Street Journal, study results were heralded by many of the 30,000 cancer specialists in attendance as “a breakthrough” with the potential to change the direction of mainstream cancer treatment protocols.

Among the more interesting cancer study results were increased survival rates for some of the new immunotherapy drugs either alone or in combination with other drugs. The conference was the first time long-term results were reported for some of the most promising new cancer drugs currently in development.

Immunotherapy treatments are designed to work with the patient’s own immune system, stimulating it to target and destroy cancer cells. Many members of the cancer community believe immunotherapy is revolutionizing the way we treat cancer. A growing history of success indicates that immunotherapy treatment protocols have the potential to significantly improve survival rates in patients with many types of tumors, including often fatal lung and kidney cancer. Of equal importance is growing evidence that immunotherapy can successfully treat advanced stages of cancer.

Immunotherapy cancer treatments are already used extensively in alternative cancer therapy. Our founder, the renowned German cancer specialist Dr. Josef M. Issels, was an early pioneer in the use of immunotherapy to treat cancer. Issels Integrative Oncology Centers have more than 60 years of experience using immunotherapy to successfully treat a wide variety of cancers at all stages of development.